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INTRODUCTION
Fetal tachyarrhythmias occur in 1% to 2% of all
pregnancies [1]. Fetal atrial flutter (AF) is the sec-
ond most common fetal tachyarrhythmia among
congenital arrhythmias diagnosed prenatally [2].
Recognition of fetal AF has increased in the past
two decades because of the common use of obstetric
ultrasound, prenatal heart rate monitoring, and close
observation of high-risk obstetric patients [3]. AF
is associated with re-entrant supraventricular
tachycardia, atrial septal defect, hypoplastic left heart
syndrome, Ebstein’s malformation of the tricuspid
valve, and cardiomyopathy [4]. Fetal hydrops is
present in 38.6% of all fetuses with AF, especially
in re-entrant supraventricular tachycardia, when the
ventricular rate exceeds 210 bpm [5]. AF seems to
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have a poor prognosis, due in part to its association
with structural heart disease (in up to 20% of cases)
and with the development of hydrops fetalis [6].
Early detection and treatment are essential to improve
outcome. We present the case of a patient with fetal
AF who received both intrauterine and postnatal
treatment.
CASE REPORT
A healthy, 32-year-old female, gravida 3, para 0, had
uneventful prenatal examinations until 34 weeks
of gestation, when fetal tachycardia was found;
she was then referred to our hospital. M-mode ultra-
sound revealed an atrial rate of 462 bpm and a
ventricular rate of 231 bpm. AF with 2:1 atrioven-
tricular block was diagnosed (Figs. 1–3). High-dose
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rapid digitalization (digoxin 0.25 mg intrave-
nously, iv, every 6 hours, q6h) was prescribed.
Three days later, quinidine (200 mg oral q6h) was
added due to persistent fetal tachycardia. Despite
medical treatment with digoxin and quinidine
for 1 week, fetal cardioechogram showed persistent
AF with tricuspid regurgitation and pericardial
effusion. Cesarean section was arranged at 36
weeks of gestation for impending heart failure. A
2,120 g male infant was born with Apgar scores
of 7 at 1 minute and 9 at 5 minutes.
Neonatal electrocardiogram revealed AF and
2:1 atrioventricular block. Parenteral digitalization
(digoxin 20 +g iv) was commenced approximately
1 hour after delivery. As persistent arrhythmia and
frequent episodes of hypotension were noted,
cardioversion was performed, leading to a sinus
rhythm of 120 bpm. Postnatal cardiogram showed
a 3.2 mm patent ductus arteriosus, a 5 mm atrial
septum defect, and a 67% left ventricular ejection
fraction. After cardioversion, a maintenance dose of
digoxin (6 +g q12h iv) was given for 1 day, after
which, as there was no further attack of arrhythmia,
the dose was tapered. Since discharge, the infant was
followed up closely without medication at pediatrics
clinics, and has demonstrated normal development
up to the time of writing (at 2 years of age).
DISCUSSION
AF accounts for one-fifth to one-third of all fetal
tachyarrhythmias [7]. It is defined as a rapid regu-
lar atrial rate of 300 to 600 bpm accompanied by
variable degrees of atrioventricular block, resulting
in slower ventricular rates [3]. In M-mode ultra-
sound, the atrial rate is faster than the ventricular
rate, and there is intermittent (often 2:1) atrial-to-
ventricular conduction.
Prenatal management and prognosis of a fetus
with AF depend on the gestational age at onset, and
the development of heart failure or hydropic change.
Where there is no evidence of heart failure, or if
the tachycardia is intermittent, it may be reasonable
to observe and deliver the affected fetus near term
[2,7,8]. If the AF can lead to heart failure and there
is a high risk of intrauterine or neonatal death, ag-
gressive treatment is necessary. Our case had persis-
tent tachycardia with pericardial effusion and was
a candidate for prenatal therapy. Krapp et al re-
ported successful treatment of non-hydropic fetuses
Fig. 1. M-mode ultrasound reveals an atrial rate of 462
bpm and a ventricular rate of 231 bpm.
Fig. 3. The atrial rate is faster than the ventricular rate,
with 2:1 atrial-to-ventricular conduction.
Fig. 2. The atrial rate is continuously greater than 400
bpm.
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with AF in 50% to 55% of cases with digoxin alone
[5]. If AF persists, then consideration should be
given to the addition of flecainide or verapamil
under close monitoring. The prognosis of the hy-
dropic fetus is considerably worse and less re-
sponsive to therapy than that of the non-hydropic
fetus. Fetuses that die in utero have associated fetal
hydrops, structural cardiac defects, or both. Lisowski
et al reported a success rate with anti-arrhythmic
drugs (of which digoxin and flecainide are the first
choices for fetal tachycardia) of 43.3% and 80% in
hydropic and non-hydropic groups, respectively [8].
Our patient did not receive direct fetal therapy
with digoxin because the pregnancy was near term
and the fetus did not respond to initial transplacental
therapy. Postnatal direct treatment may achieve a
sinus rhythm with fewer potential adverse effects to
the mother and the fetus. After birth, a normal sinus
rhythm was achieved successfully through
electrocardioversion. Further prospective studies are
needed to disentangle the effects of preterm delivery
versus intrauterine management of fetal AF with
hydrops.
REFERENCES
1. Strasburger JF. Fetal arrhythmias. Progr Pediatr
Cardiol 2000;11:1–17.
2. Kleinman CS. Prenatal diagnosis and management of
intrauterine arrhythmias. Fetal Ther 1986;1:92–5.
3. Cotton JL. Identification of fetal atrial flutter by Doppler
tissue imaging. Circulation 2001;104:1206–7.
4. Strasburger JF, Duffy E, Gidding SS. Abnormal
Doppler flow patterns in atrial tachycardia in infants.
Am J Cardiol 1997;80:27–30.
5. Krapp M, Kohl T, Simpson JM, et al. Review of
diagnosis, treatment, and outcome of fetal atrial flutter
compared with supraventricular tachycardia. Heart
2003;89:913–7.
6. Simpson LL, Marx GR. Diagnosis and treatment of
structural fetal cardiac abnormality and dysrhythmia.
Semin Perinatol 1994;18:215–27.
7. Jaeggi E, Fouron JC, Drblik SP. Fetal atrial flutter:
diagnosis, clinical features, treatment, and outcome.
J Pediatr 1998;132:335–9.
8. Lisowski LA, Verheijen PM, Benatar AA, et al. Atrial
flutter in the perinatal age group: diagnosis, man-
agement and outcome. J Am Coll Cardiol 2000;35:
771–7.
